Brian G. Weinshenker, MD

September 21, 2021

Mayo Clinic’s Brian G. Weinshenker, MD, compares multiple sclerosis with neuromyelitis optica spectrum disorders (NMOSD) and explains why community neurologists need to receive more education on NMOSD risk factors and symptoms.

August 20, 2021

The professor of neurology at the Mayo Clinic College of Medicine highlighted the importance of the diagnostic process and implementing an early treatment regimen for patients with NMOSD.

August 17, 2021

The professor of neurology at Mayo Clinic College of Medicine discussed which biomarkers have shown the most relevancy in NMOSD and which deserve more attention.

August 14, 2021

The professor of neurology at Mayo Clinic College of Medicine discussed several areas within the neuromyelitis optica spectrum disorder that are of interest for ongoing and new research efforts.

August 13, 2021

The professor of neurology at Mayo Clinic College of Medicine discussed the 3 currently FDA-approved agents for NMOSD and other agents currently within the clinical pipeline.

August 12, 2021

The professor of neurology at Mayo Clinic College of Medicine discussed lesser-known facets of NMOSD and how the disease evolves over time.

August 11, 2021

The professor of neurology at the Mayo Clinic College of Medicine detailed the strides made in recognizing NMOSD as its own disease, along with specific biomarkers that identify it.

August 05, 2021

The professor of neurology at the Mayo Clinic College of Medicine discussed the need for evaluating infection risk of disease-modifying therapies amid a growing MS treatment landscape.